1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Anti-Viral Therapies Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Anti-Viral Therapies Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Anti-Viral Therapies Market Regional Analysis
6.2 North America Anti-Viral Therapies Market Revenue 2017-2027 (US$ Million)
6.3 North America Anti-Viral Therapies Market Forecast Analysis
7. North America Anti-Viral Therapies Market Analysis – by Type
7.1 Generic Drugs
- 7.1.1 Overview
- 7.1.2 Generic Drugs: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Branded Drugs
- 7.2.1 Overview
- 7.2.2 Branded Drugs: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. North America Anti-Viral Therapies Market Analysis – by Mechanism of Action
8.1 Nucleotide Polymerase Inhibitors
- 8.1.1 Overview
- 8.1.2 Nucleotide Polymerase Inhibitors: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Reverse Transcriptase Inhibitors
- 8.2.1 Overview
- 8.2.2 Reverse Transcriptase Inhibitors: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Protease Inhibitors
- 8.3.1 Overview
- 8.3.2 Protease Inhibitors: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. North America Anti-Viral Therapies Market Analysis – by Application
9.1 HIV
- 9.1.1 Overview
- 9.1.2 HIV: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Hepatitis
- 9.2.1 Overview
- 9.2.2 Hepatitis: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Virus Influenza
- 9.3.1 Overview
- 9.3.2 Virus Influenza: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.4 Herpes
- 9.4.1 Overview
- 9.4.2 Herpes: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.5 Other Applications
- 9.5.1 Overview
- 9.5.2 Other Applications: North America Anti-Viral Therapies Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. North America Anti-Viral Therapies Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Anti-Viral Therapies Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 North America Anti-Viral Therapies Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 US: North America Anti-Viral Therapies Market Breakdown, by Type
- 10.2.1.1.2 US: North America Anti-Viral Therapies Market Breakdown, by Mechanism of Action
- 10.2.1.1.3 US: North America Anti-Viral Therapies Market Breakdown, by Application
- 10.2.1.2 Canada:
North America Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Canada: North America Anti-Viral Therapies Market Breakdown, by Type
- 10.2.1.2.2 Canada: North America Anti-Viral Therapies Market Breakdown, by Mechanism of Action
- 10.2.1.2.3 Canada: North America Anti-Viral Therapies Market Breakdown, by Application
- 10.2.1.3 Mexico :
North America Anti-Viral Therapies Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 Mexico : North America Anti-Viral Therapies Market Breakdown, by Type
- 10.2.1.3.2 Mexico : North America Anti-Viral Therapies Market Breakdown, by Mechanism of Action
- 10.2.1.3.3 Mexico : North America Anti-Viral Therapies Market Breakdown, by Application
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Abbott
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 AbbVie Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bristol-Myers Squibb Company
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Johnson and Johnson Services, Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck & Co., Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Gilead Sciences, Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For North America Anti-Viral Therapies Market
